Zymeworks Inc. (ZYME)

The company now

Zymeworks licensed its DLL3 cancer drug candidate ZW209 to Roche on 22 October 2026 1. Roche is to pay $55.0 million upfront and $40.0 million when a Phase Ib trial starts, plus up to $718 million in milestones, or up to $813 million in all (computed) 1.

The license starts only after United States antitrust clearance 1. Roche pays for the opening human trial that Zymeworks will run, and Zymeworks is eligible for royalties from the high single digits to the mid-teens on any sales 1.

The FDA approved Ziihera, a cancer antibody Zymeworks discovered and its partner Jazz sells, for first-line HER2-positive stomach and esophageal cancer on 25 August 2026 517. That earned Zymeworks a $250 million milestone payment 5.

On 23 September 2026 Zymeworks completed its purchase of Theravance Biopharma, adding YUPELRI, a medicine promoted in hospitals, to its royalty income 34. The company then said it expects 2026 revenue of $278 million to $292 million 4.

The latest quarterly report on file covers the three months to 30 June 2026, before these deals, when revenue was $4.6 million 7. Third-quarter results are due on 9 November 2026 11.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.